title: Hyperkeratosis of nipple skin during sorafenib treatment.
authors.forename: Marta
authors.initials: M
authors.lastname: Frigerio
authors.forename: Valentina
authors.initials: V
authors.lastname: Santi
authors.forename: Antonio
authors.initials: A
authors.lastname: Di Micoli
authors.forename: Franco
authors.initials: F
authors.lastname: Trevisani
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000009:adverse effects*; D001941:Breast Diseases / Q000139:chemically induced; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D006801:Humans; D007642:Keratosis / Q000139:chemically induced*; D008113:Liver Neoplasms / Q000188:drug therapy; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D009558:Nipples / Q000187:drug effects / Q000473:pathology*; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib